UNLIMITED TURBO SHORT - MODERNA | Market Closed - Börse Stuttgart 03:50:43 2024-05-31 pm EDT | ||
| 14.3 EUR | +5.54% |
|
| Current month | -18.52% | ||
| 1 month | -18.52% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 14.3 | +5.54% |
| 24-05-30 | 13.55 | -2.45% |
| 24-05-29 | 13.89 | +3.73% |
| 24-05-28 | 13.39 | +10.94% |
| 24-05-27 | 12.07 | -0.58% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 03:50 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PE6RJX |
| ISIN | DE000PE6RJX0 |
| Date issued | 2022-12-15 |
| Strike | 295.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 9.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.03 € |
|---|---|
| Lowest since issue | 8.51 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
142.6
USD
Average target price
138.8
USD
Spread / Average Target
-2.65%
- Stock Market
- Certificates
- Certificat
